In a study, Janssen Pharmaceuticals' once-a-month injectable for schizophrenia resulted in better outcomes than daily oral competitors, as measured by real-world (as opposed to strictly clinical) outcomes like arrest or psychiatric hospitalization.
A month after Genmab and Johnson & Johnson's Janssen released successful mid-stage data for its multiple myeloma antibody daratumumab, Halozyme has jumped on board, planning a Phase I trial with its subcutaneous delivery technology. Read more >>
Citing rampant use of the same needle to inject more than one person, the World Health Organization has--some might say finally--launched a new policy to make unsafe injections less prevalent. Part of this policy involves adopting up-to-date measures in syringe engineering, promoting the use of "smart" needles with precautions against unsafe use. Read more >>
POPULAR COMMENT THREADS
Icon Bioscience has brought to light data from its late-stage extended-release cataract treatment, which demonstrated a high level of efficacy while reducing inflammation after surgery.
The stomach and the gut are difficult places for DNA to survive and eventually pass into the bloodstream intact. Now researchers have developed nanoparticle-coated bacteria that can someday be used to create effective DNA vaccines.
Johnson & Johnson's diabetes care business experienced a year-over-year revenue decline of 2.2% in 2015 and fell 8.7% for the year. But J&J executives are optimistic about a turnaround, citing the recent launch of the drug-delivering Animas Vibe continuous glucose monitor and insulin pump, and longer term plans for a wearable insulin pump.
Fierce 15 member Mersana Therapeutics, a developer of customizable next-generation antibody-drug conjugates, announced that its lead anticancer candidate showed promise in preclinical studies.
The elimination of the Medicare Sustained Growth Rate formula that threatened large Medicare reimbursement cuts to doctors on an annual basis is the most significant entitlement reform achieved by the new Congress.
Under the guidance of drug delivery guru Dr. Robert Langer of MIT and Massachusetts General Hospital's Dr. William Crowley, Boston's Columbia Laboratories has acquired the license to an intravaginal ring designed to deliver several different drugs at a time.
From Our Sister Sites
Neuronetics has closed a $34.3 million Series F round to further commercialize its NeuroStar transcranial magnetic stimulation (TMS) therapy system to treat drug-resistant major depressive disorder (MDD), as well as to fund a registration study for adolescent use of the device. NeuroStar was cleared by FDA in 2008 to treat MDD, but the company said it's just recently been gaining traction with payers.
The world's top sellers of the world's top biologic meds haven't changed much in the last few years. Ranked by 2014 sales, it's your usual suspects--Roche, Amgen, Novo Nordisk, AbbVie. But as PMLiVE notes in its annual ranking, times are a-changing.